Cellular Biomedicine Group acquires GVAX vaccine

Cellular Biomedicine Group acquire CD40LGVAX vaccine
Cellular Biomedicine Group acquire CD40LGVAX vaccine | Courtesy of
Cellular Biomedicine Group Inc., a biomedicine company that focuses on creating new treatments for cancerous and degenerative diseases, recently announced that it has acquired the CD40LGVAX vaccine from Blackbird Bio Finance and the University of Florida.

The acquisition of the next-generation GVAX vaccine includes the related technologies and knowledge. Finalizing this acquisition allows Cellular Biomedicine Group to provide comprehensive immuno-oncology cell therapy within the company’s portfolio. The company can also now provide patients with a wider variety of treatment options.

Cellular Biomedicine Group has agreed to pay $2.5 million in cash as an initial consideration as well as up to $1.75 million in the company’s shares of common stock. The stock is established on the 20-day volume, which is the weighted average price as of the closing date on June 20. Now that the company is a licensee of the vaccine, it may need to pay over $25 million for future sales and milestones.

"We are extremely pleased with this strategic acquisition which strengthens our cancer immunotherapy vaccine and vaccine combination technology platform,” William (Wei) Cao, chief executive officer of Cellular Biomedicine Group, said. “This inroad into the U.S. market is a significant milestone for the company and we look forward to seeking approval to conduct international clinical trials with leading medical centers."

Organizations in this Story

Cellular Biomedicine Group Inc

Want to get notified whenever we write about Cellular Biomedicine Group Inc ?
Next time we write about Cellular Biomedicine Group Inc, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.